Loading clinical trials...
Loading clinical trials...
To evaluate the capability to monitor LBB success criteria with the use of a Smart ECG system (ECG monitor, 12 leads ECG cable, ECG viewer software ) during a cardiac device implantation involving the placement of a pacing lead in interventricular septum area
The clinical investigation aims to support physicians with a portable and easy to use solution to display ECG and to provide automatic calculation of key ECG indicators (Left Ventricular Activation time (LVAT) and V6-V1 interval) for LBB implantation procedure. This allows physicians to concentrate on lead placement with the benefice from immediate ECG measurements thanks to the automatic software. The Smart ECG system is class IIA device and it is composed of: 1. CE-marked Smart ECG, Class IIa medical device (rule 10 Annex VIII of MDR) 2. ECG viewer Software (HookUp SmarV2) (providing 12 lead ECG display + automatic interval measurements + shadow plot for QRS visualization) Class IIa medical device (rule 11 Annex VIII of MDR). 3. CE -marked 12 leads ECG cables radiotransparent and defibrillation proof (Class I device) 4. Commercial PC used in combination with the devices under evaluation The study is a pre-market, non-pivotal study: HookUp Smart V2 software is a non-implantable Class IIA device, with no interaction with the human body and the demonstration of conformity with general safety and performance requirements is based on the results of non-clinical testing methods alone (as article 61(10) from MDR.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
CHU de Besançon
Besançon, France, France
Clermont Ferrand
Clermont-Ferrand, France, France
CHU Grenoble Alpes
Grenoble, France, France
Clinique du Millénaire
Montpellier, France, France
Start Date
November 14, 2025
Primary Completion Date
February 28, 2026
Completion Date
March 31, 2026
Last Updated
December 5, 2025
55
ESTIMATED participants
LBBAP implant
DEVICE
Lead Sponsor
MicroPort CRM
NCT07221682
NCT03008291
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07290595